Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia
Hoffmann-La Roche
Hoffmann-La Roche
Hoffmann-La Roche
Gilead Sciences
Hoffmann-La Roche
TG Therapeutics, Inc.
Celgene
German CLL Study Group
Hoffmann-La Roche
Hoffmann-La Roche
Hoffmann-La Roche
Pharmacyclics LLC.
Hoffmann-La Roche
Genentech, Inc.
Hoffmann-La Roche
National Cancer Institute (NCI)
Jiangsu Simcere Pharmaceutical Co., Ltd.